Antiplatelet therapy beyond 2012

Role of personalized medicine

Udaya S. Tantry, Andrzej Budaj, Paul A. Gurbel

Research output: Contribution to journalArticle

Abstract

Since its first approval in 1997, clopidogrel has revolutionized interventional cardiology and transformed therapy for non-ST-segment elevation myocardial infarction (NSTEMI), STEMI, and percutaneous coronary intervention-treated patients. It enjoyed a remarkable 15-year "homerun" in the world market without any major competition. With the introduction of more potent P2Y12 receptor blockers, the current antiplatelet strategy is undergoing a transition period. Generic clopidogrel is inexpensive and pharmacodynamically effective in at least two thirds of the patients with coronary artery disease. The unpredictable, slow onset, and overall modest pharmacodynamic effects are the major limitations of clopidogrel. The new, more potent P2Y12 receptor blockers overcome the limitations of clopidogrel therapy and are associated with better clinical efficacy, but are more costly and associated with more bleeding. In this scenario, personalization of antiplatelet therapy based on platelet function and genetic testings to strike a balance between cost, benefit, and safety is a potential option. Copyright by Medycyna Praktyczna, 2012.

Original languageEnglish (US)
Pages (from-to)298-305
Number of pages8
JournalPolskie archiwum medycyny wewn&x0229;trznej
Volume122
Issue number6
StatePublished - 2012

Fingerprint

clopidogrel
Precision Medicine
Genetic Testing
Percutaneous Coronary Intervention
Therapeutics
Cardiology
Cost-Benefit Analysis
Coronary Artery Disease
Blood Platelets
Hemorrhage
Safety

Keywords

  • Antiplatelet therapy
  • Clopidogrel
  • P2Y receptor blockers
  • Prasugrel
  • Ticagrelor

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Tantry, U. S., Budaj, A., & Gurbel, P. A. (2012). Antiplatelet therapy beyond 2012: Role of personalized medicine. Polskie archiwum medycyny wewn&x0229;trznej, 122(6), 298-305.

Antiplatelet therapy beyond 2012 : Role of personalized medicine. / Tantry, Udaya S.; Budaj, Andrzej; Gurbel, Paul A.

In: Polskie archiwum medycyny wewn&x0229;trznej, Vol. 122, No. 6, 2012, p. 298-305.

Research output: Contribution to journalArticle

Tantry, US, Budaj, A & Gurbel, PA 2012, 'Antiplatelet therapy beyond 2012: Role of personalized medicine', Polskie archiwum medycyny wewn&x0229;trznej, vol. 122, no. 6, pp. 298-305.
Tantry, Udaya S. ; Budaj, Andrzej ; Gurbel, Paul A. / Antiplatelet therapy beyond 2012 : Role of personalized medicine. In: Polskie archiwum medycyny wewn&x0229;trznej. 2012 ; Vol. 122, No. 6. pp. 298-305.
@article{abfccc2d595944b3b6bdce8031a80951,
title = "Antiplatelet therapy beyond 2012: Role of personalized medicine",
abstract = "Since its first approval in 1997, clopidogrel has revolutionized interventional cardiology and transformed therapy for non-ST-segment elevation myocardial infarction (NSTEMI), STEMI, and percutaneous coronary intervention-treated patients. It enjoyed a remarkable 15-year {"}homerun{"} in the world market without any major competition. With the introduction of more potent P2Y12 receptor blockers, the current antiplatelet strategy is undergoing a transition period. Generic clopidogrel is inexpensive and pharmacodynamically effective in at least two thirds of the patients with coronary artery disease. The unpredictable, slow onset, and overall modest pharmacodynamic effects are the major limitations of clopidogrel. The new, more potent P2Y12 receptor blockers overcome the limitations of clopidogrel therapy and are associated with better clinical efficacy, but are more costly and associated with more bleeding. In this scenario, personalization of antiplatelet therapy based on platelet function and genetic testings to strike a balance between cost, benefit, and safety is a potential option. Copyright by Medycyna Praktyczna, 2012.",
keywords = "Antiplatelet therapy, Clopidogrel, P2Y receptor blockers, Prasugrel, Ticagrelor",
author = "Tantry, {Udaya S.} and Andrzej Budaj and Gurbel, {Paul A.}",
year = "2012",
language = "English (US)",
volume = "122",
pages = "298--305",
journal = "Polskie Archiwum Medycyny Wewnetrznej",
issn = "0032-3772",
publisher = "Medycyna Praktyczna",
number = "6",

}

TY - JOUR

T1 - Antiplatelet therapy beyond 2012

T2 - Role of personalized medicine

AU - Tantry, Udaya S.

AU - Budaj, Andrzej

AU - Gurbel, Paul A.

PY - 2012

Y1 - 2012

N2 - Since its first approval in 1997, clopidogrel has revolutionized interventional cardiology and transformed therapy for non-ST-segment elevation myocardial infarction (NSTEMI), STEMI, and percutaneous coronary intervention-treated patients. It enjoyed a remarkable 15-year "homerun" in the world market without any major competition. With the introduction of more potent P2Y12 receptor blockers, the current antiplatelet strategy is undergoing a transition period. Generic clopidogrel is inexpensive and pharmacodynamically effective in at least two thirds of the patients with coronary artery disease. The unpredictable, slow onset, and overall modest pharmacodynamic effects are the major limitations of clopidogrel. The new, more potent P2Y12 receptor blockers overcome the limitations of clopidogrel therapy and are associated with better clinical efficacy, but are more costly and associated with more bleeding. In this scenario, personalization of antiplatelet therapy based on platelet function and genetic testings to strike a balance between cost, benefit, and safety is a potential option. Copyright by Medycyna Praktyczna, 2012.

AB - Since its first approval in 1997, clopidogrel has revolutionized interventional cardiology and transformed therapy for non-ST-segment elevation myocardial infarction (NSTEMI), STEMI, and percutaneous coronary intervention-treated patients. It enjoyed a remarkable 15-year "homerun" in the world market without any major competition. With the introduction of more potent P2Y12 receptor blockers, the current antiplatelet strategy is undergoing a transition period. Generic clopidogrel is inexpensive and pharmacodynamically effective in at least two thirds of the patients with coronary artery disease. The unpredictable, slow onset, and overall modest pharmacodynamic effects are the major limitations of clopidogrel. The new, more potent P2Y12 receptor blockers overcome the limitations of clopidogrel therapy and are associated with better clinical efficacy, but are more costly and associated with more bleeding. In this scenario, personalization of antiplatelet therapy based on platelet function and genetic testings to strike a balance between cost, benefit, and safety is a potential option. Copyright by Medycyna Praktyczna, 2012.

KW - Antiplatelet therapy

KW - Clopidogrel

KW - P2Y receptor blockers

KW - Prasugrel

KW - Ticagrelor

UR - http://www.scopus.com/inward/record.url?scp=84863761501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863761501&partnerID=8YFLogxK

M3 - Article

VL - 122

SP - 298

EP - 305

JO - Polskie Archiwum Medycyny Wewnetrznej

JF - Polskie Archiwum Medycyny Wewnetrznej

SN - 0032-3772

IS - 6

ER -